Oppenheimer keeps an Outperform rating on Regeneron (REGN) with a $925 price target after the FDA denied the company’s attempt to extend the ...

Shares of Charles River Labs (CRL) crashed 28% after the U.S. FDA (Food and Drug Administration) announced plans to phase out the need for ...